Rani Therapeutics - Class A opened lower at $0.56, compared with its previous close of $0.57. In the last trading session, the stock traded between $0.53 and $0.58. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Rani Therapeutics - Class A is now worth
$ 1.85
Resulting in a loss of
$ 98.15 (98.15%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-7.04%)
Day High
$0.58
Day Low
$0.53
Day Open
$0.56
Prev Close
$0.57
Volume
6,93,010
1W Return
-8.65%
1M Return
-29.79%
3M Return
-32.99%
6M Return
-50.65%
1Y Return
-72.78%
Fundamentals
Market Cap ($ Mn)
61
PE Ratio
-
PB Ratio
2.42
PEG Ratio
-
ROE
-1,106.10%
ROCE
-360.32%
EPS (TTM)
$-0.07
Investment Returns
1 Week
-8.65%
1 Month
-29.79%
3 Months
-32.99%
6 Months
-50.65%
9 Months
-59.07%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
1.5
Dec 25
1.7
Mar 26
1.7
Jun 26
1.7
Sep 26
Updates
10Nov
Rani Therapeutics Q3 Results: Loss narrows 67%, revenue beats estimate
Quarterly loss of $(0.04) per share beat the $(0.05) analyst estimate. Revenue of $1.707 million exceeded consensus by 33.41%. Per-share loss narrowed 66.67% YoY from $(0.12).
3 days ago
21Aug
HC Wainwright reiterates Buy on Rani Therapeutics, keeps $11 target
HC Wainwright & Co. reiterates a Buy rating on Rani Therapeutics Holdings. The $11 price target remains unchanged from previous estimates. Analyst Brandon Folkes confirms the continued positive outlook.
2mo ago
18Aug
Chardan Capital initiates coverage on Rani Therapeutics with $6 price target
Chardan Capital has initiated coverage on Rani Therapeutics Holdings (NASDAQ: RANI) with a Buy rating and a $6 price target. Analyst Andreas Argyrides led the research note, marking the firm's first formal view on the biotechnology company.
2mo ago
14Aug
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85%
Rani Therapeutics Holdings reported Q2 EPS of $(0.04), beating the $(0.05) estimate by 20%. Sales of $1.708 million exceeded the $925,000 consensus by 84.65%, showing strong top-line momentum.
3mo ago
21Jul
Rani Therapeutics grants 2M stock options to new CFO Nicholas Maestas
Rani Therapeutics granted 2,000,000 stock options to new CFO Nicholas Maestas at $0.6973 per share as an employment inducement. The options vest over four years, with 25% vesting after one year and the remainder in equal monthly installments. The grant was approved under Nasdaq Listing Rule 5635(c)(4).
Rani Therapeutics Holdings, Inc. reported positive initial Phase 1 data for RT-114, showing systemic exposure greater than 150% relative to a matched subcutaneous dose with a consistent safety profile. The Phase 1a study is expanding to further define pharmacokinetics before a planned Phase 1b study in obesity patients.
